BrightPath Biotherapeutics Co Ltd 4594
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- JPY 59.00
- Day Range
- JPY 59.00–60.00
- 52-Week Range
- JPY 56.00–161.00
- Bid/Ask
- JPY 59.00 / JPY 60.00
- Market Cap
- JPY 3.92 Bil
- Volume/Avg
- 87,800 / 877,760
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
BrightPath Biotherapeutics Co Ltd is a biopharmaceutical venture company. It is engaged in developing novel cancer immunotherapeutics. Its products include two candidate products: ITK-1 and GRN-1201 which are in the clinical trial stage.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 33
- Website
- https://www.brightpathbio.com
Comparables
Valuation
|
Metric
|
4594
|
4893
|
4563
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 4.95 | 1.24 | 0.38 |
Price/Sales | — | 21.34 | 61.87 |
Price/Cash Flow | — | — | — |
Price/Earnings
4594
4893
4563
Financial Strength
|
Metric
|
4594
|
4893
|
4563
|
|---|---|---|---|
Quick Ratio | 2.17 | 65.18 | 1.68 |
Current Ratio | 2.31 | 66.28 | 2.38 |
Interest Coverage | −26,349.35 | — | — |
Quick Ratio
4594
4893
4563
Profitability
|
Metric
|
4594
|
4893
|
4563
|
|---|---|---|---|
Return on Assets (Normalized) | −78.20% | −19.85% | −16.00% |
Return on Equity (Normalized) | −92.78% | −20.61% | −19.90% |
Return on Invested Capital (Normalized) | −86.10% | −20.61% | −19.26% |
Return on Assets
4594
4893
4563
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Pkwftwvmd | Ndvlq | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Dkmqdqw | Qxwsbld | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Mwlngcbh | Jcmqx | $99.5 Bil | |
MRNA
| Moderna Inc | Wxjcnyqwn | Zzh | $38.8 Bil | |
ARGX
| argenx SE ADR | Nbywsjnz | Yjr | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Wdphykyz | Mhdd | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Fdqcjwzyg | Ngjyczq | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Rrbjfvxt | Wlqphb | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Vxtskmtfvx | Btvnhq | $12.5 Bil | |
INCY
| Incyte Corp | Sthwpnjx | Dczyst | $11.6 Bil |